



PARTICIPANT STATISTICS

SECOND QUADRIMESTER 2016

ORAL FLUIDS HIV-1 ANTIBODIES

anti-HIV-1 Screening

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5			
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	
Avioq HIV-1	18				18			18			18			18		
Bio-Rad GS HIV 1/2 Plus O	3				3			3			3			3		
*In-house validated method		4			4			4			2	2		2	2	
OraQuick ADVANCE Rapid	2				2			2			2			2		
OraQuick ADVANCE, Wv	1				1			1			1			1		
Total Population	24	4	0	0	28	0	0	28	0	26	2	0	26	2	0	
Flagging		***	***	***		***	***		***		***	***		***	***	

* 4th Generation Ag/Ab Combo kits reacted to the p24 antigen as would be expected. They were evaluated against both antigen and antibody. If your kit reports serology and antigen independently, you must report antigen detection separately or be flagged.

anti-HIV-1 Confirmation

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Neg, TNP	Neg	Ind	Neg, TNP	Neg	Ind	Neg, TNP	Neg	Ind	Neg, TNP	Neg	Pos	Neg, TNP
OraSure Western Blot	15		10		25			25		14		11	14		11
Total Population	15	0	10	0	25	0	0	25	0	14	0	11	14	0	11
Flagging		***		***		***	***		***		***			***	

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.